BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIOA BioAge Labs Inc.

Trading 07-31 12:51:18 EDT

9.46

-15.39

-61.95%

High10.81	Low8.65	Vol6.03M
Open8.77	D1 Closing24.85	Amplitude8.69%
Mkt Cap419.61M	Tradable Cap330.47M	Total Shares44.38M
T/O59.40M	T/O Rate17.26%	Tradable Shares34.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":9.455,"timestamp":1785516677023,"preClose":24.85,"halted":0,"volume":6033514,"delay":0,"changeRate":-0.6195171026156941,"floatShares":34951419,"shares":44379800,"eps":-2.392358,"marketStatus":"Trading","change":-15.395,"latestTime":"07-31 12:51:18 EDT","open":8.77,"high":10.81,"low":8.65,"amount":59396813.936234,"amplitude":0.086922,"askPrice":9.5,"askSize":100,"bidPrice":9.41,"bidSize":373,"shortable":0,"etf":0,"ttmEps":-2.392358,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785528000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":24.85,"preHourTrading":{"tag":"盘前","latestPrice":8.6801,"preClose":24.85,"latestTime":"09:29 EDT","volume":407212,"amount":4071048.218016,"timestamp":1785504596707,"change":-16.1699,"changeRate":-0.6507,"amplitude":0.70604},"postHourTrading":{"tag":"盘后","latestPrice":26,"preClose":24.85,"latestTime":"19:52 EDT","volume":24830,"amount":623556.9498,"timestamp":1785455559723,"change":1.15,"changeRate":0.046278,"amplitude":0.065996},"volumeRatio":15.18172,"impliedVol":0.7893,"impliedVolPercentile":0.3625},"requestUrl":"/m/hq/s/BIOA/wiki","defaultTab":"wiki","newsList":[{"id":"2655869917","title":"Sales of Leqembi® Totaled 29.3 Billion Yen in the Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655869917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655869917?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:30","pubTimestamp":1785321058,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUAFLZS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650045459","title":"How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure","url":"https://stock-news.laohu8.com/highlight/detail?id=2650045459","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650045459?lang=en_us&edition=fundamental","pubTime":"2026-07-10 10:22","pubTimestamp":1783650160,"startTime":"0","endTime":"0","summary":"In late June 2026, BioAge Labs, Inc. (NasdaqGS:BIOA) was added to multiple Russell Growth Benchmark Indexes, including the Russell 2000, Russell 2500, Russell 3000, Russell 3000E, Russell Microcap, and the Russell Small Cap Comp Growth indexes.\nThis broad index inclusion significantly expands BioAge Labs’ visibility among institutional investors and index-tracking funds that follow these Russell Growth benchmarks.\nNext, we’ll examine how BioAge Labs’ broad Russell Growth index inclusion...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bioa/bioage-labs/news/how-broad-russell-growth-index-inclusion-could-shape-bioage","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bioa/bioage-labs/news/how-broad-russell-growth-index-inclusion-could-shape-bioage","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648262115","title":"Bioage Labs Principal Accounting Officer Shane Barton Disposes of 62,566 Common Shares for $1,578,254.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2648262115","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648262115?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:27","pubTimestamp":1782937665,"startTime":"0","endTime":"0","summary":"BioAge Labs principal accounting officer Shane Barton disposes of 62,566 common shares for $1,578,254.20BioAge Labs principal accounting officer Shane Barton sold 62,566 shares on June 29-30, ending w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL7chPKv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bioage Labs Principal Accounting Officer Shane Barton Disposes of 62,566 Common Shares for $1,578,254.20","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644080138","title":"BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2644080138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644080138?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800375,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. ($BIOA) announced an update on their ongoing clinical study. BioAge Labs, Inc. has launched a Phase 2 trial titled “A Phase 2, Ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-moves-bge-102-into-mid-stage-obesity-heart-risk-trial-raising-new-investor-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-moves-bge-102-into-mid-stage-obesity-heart-risk-trial-raising-new-investor-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644741614","title":"Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644741614","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644741614?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:30","pubTimestamp":1781703053,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bioage-labs-inc-bioa-karyopharm-therapeutics-kpti-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bioage-labs-inc-bioa-karyopharm-therapeutics-kpti-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007","BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644748499","title":"Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644748499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644748499?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:00","pubTimestamp":1781694034,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN) with neutral ratings, indicating that the e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4007","LU0029874061.USD","LABU","BK4139","LU0128526141.USD","VRDN","BK4581","XBI","BIOA","BK4137","XLV","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643752300","title":"BioAge doses first participant in Phase 2 QUELL-CV trial of NLRP3 inhibitor BGE-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2643752300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643752300?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:16","pubTimestamp":1781612195,"startTime":"0","endTime":"0","summary":"BioAge Labs dosed the first participant in QUELL-CV, a Phase 2 trial of oral NLRP3 inhibitor BGE-102 for cardiovascular risk reduction.Study will test three once-daily doses versus placebo in 160 adults with obesity and elevated inflammation.Readout will assess whether BGE-102 lowers systemic inflammation, guiding dose selection for a planned Phase 3 program.Phase 1 results were previously reported, showing the drug reduced inflammation and was well tolerated.Topline Phase 2 data are expected in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL4npzzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754046","title":"Bioage Labs - Topline Data From Quell-Cv Trial Anticipated in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754046?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:00","pubTimestamp":1781611201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUABNWHLK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643480754","title":"Bioage Labs Announces First Participant Dosed in Quell-Cv, a Phase 2 Proof-of-Concept Trial of Bge-102, a Novel Oral Nlrp3 Inhibitor, in Patients at Elevated Cardiovascular Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2643480754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643480754?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:00","pubTimestamp":1781611201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUABNWHLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643375404","title":"Bioage Labs - to Initiate Phase 1B/2a Trial of Bge-102 in Dme in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643375404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643375404?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:00","pubTimestamp":1781611201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUABNWHLK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642298022","title":"BioAge Labs Shareholders Reelect Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2642298022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642298022?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:34","pubTimestamp":1781267666,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BioAge Labs, Inc. ( ($BIOA) ). On June 10, 2026, BioAge Labs, Inc. stockholders elected three Class II director...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-labs-shareholders-reelect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-labs-shareholders-reelect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260070","title":"BioAge Labs shareholders re-elect three directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642260070?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:02","pubTimestamp":1781265724,"startTime":"0","endTime":"0","summary":"BioAge Labs held its 2026 annual stockholder meeting on June 10, 2026.Stockholders elected Patrick Enright, James I. Healy, Rekha Hemrajani as Class II directors; the election was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL6PBk6t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642588684","title":"BioAge Labs posts preclinical data on oral NLRP3 inhibitor BGE-102 in diabetic retinopathy model","url":"https://stock-news.laohu8.com/highlight/detail?id=2642588684","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642588684?lang=en_us&edition=fundamental","pubTime":"2026-06-09 08:30","pubTimestamp":1780965038,"startTime":"0","endTime":"0","summary":"BioAge Labs published preclinical results for oral NLRP3 inhibitor BGE-102 in a streptozotocin-induced diabetic retinopathy mouse model.BGE-102 cut retinal vascular permeability versus vehicle by 74% at 20 mg/kg, 98.7% at 50 mg/kg; higher dose restored angiography to healthy levels.Claudin-5 staining showed tight-junction integrity restored to 95% to 97% of healthy control levels despite persistent hyperglycemia.Findings support a planned Phase 1b/2a trial in diabetic macular edema.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on June 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL4Ztx5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642430920","title":"BioAge Labs posts Phase 1 BGE-102 presentation showing anti-inflammatory activity in obesity cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2642430920","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642430920?lang=en_us&edition=fundamental","pubTime":"2026-06-09 08:09","pubTimestamp":1780963767,"startTime":"0","endTime":"0","summary":"BioAge Labs released a medical research presentation on Phase 1 results for BGE-102, an oral NLRP3 inhibitor studied in healthy volunteers and participants with obesity.Trial readouts showed 90% ex vivo IL-1β suppression at trough at 60 mg, rising to 98% at 120 mg after 14 days.In a 120 mg multiple-ascending-dose cohort in obesity, hsCRP fell 86% at Day 14 versus 43% on placebo; 93% reached hsCRP below 2 mg/L.Safety profile showed mild-to-moderate adverse events with no serious events, no discontinuations, no dose-limiting toxicities.Data package supports moving BGE-102 into proof-of-concept studies targeting metabolic and inflammatory conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL9GrDJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638501627","title":"Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2638501627","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638501627?lang=en_us&edition=fundamental","pubTime":"2026-05-27 18:41","pubTimestamp":1779878494,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) has an average rating of buy and mean price target of $49.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638509976","title":"BioAge Labs Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2638509976","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638509976?lang=en_us&edition=fundamental","pubTime":"2026-05-27 18:18","pubTimestamp":1779877080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2026 06:18 ET (10:18 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638570432","title":"BioAge Labs initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2638570432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638570432?lang=en_us&edition=fundamental","pubTime":"2026-05-27 16:20","pubTimestamp":1779870008,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Adam Walsh initiated coverage of BioAge Labs (BIOA) with a Buy rating and $36 price target The firm believes the company’s lea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637314726","title":"BioAge Labs joins Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637314726","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637314726?lang=en_us&edition=fundamental","pubTime":"2026-05-22 21:00","pubTimestamp":1779454857,"startTime":"0","endTime":"0","summary":"BioAge Labs will attend the Jefferies Global Healthcare Conference in New York on June 3-4, 2026.A fireside chat is scheduled for June 4, 2026, from 3:45-4:15 p.m. EDT.The company will also attend the Goldman Sachs Global Healthcare Conference in Miami Beach on June 8-10, 2025, with a fireside chat set for June 8, 2025, from 2:40-3:15 p.m. EDT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLcclySm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","LU2237443549.SGD","LU2265009873.SGD","LU0345770993.USD","LU2237443978.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","BK4112","LU2210149790.SGD","BK4552","IE00BKPKM429.USD","LU2471134796.USD","IE00B19Z3581.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU0061475181.USD","LU0314104364.USD","LU2471134879.HKD","NDAQ","BIOA","LU1668664300.SGD","BK4127","LU1804176565.USD","LU1868836757.USD","LU1894683264.USD","IE0004086264.USD","LU0345770308.USD","LU1868837300.USD","LU1868836591.USD","SG9999014005.SGD","BK4007","IE00BN0W2T93.GBP","LU2750360997.AUD","LU0742534661.SGD","LU2750360641.GBP","IE00BSNM7G36.USD","LU0106831901.USD","IE00B3QW5Z07.USD","GSX","IE00B64PRP62.GBP","LU0942090050.USD","IE0002270589.USD","LU0251131958.USD","LU1791807156.HKD","LU1894683348.USD","LU2237438978.USD","LU2237443622.USD","LU0868494708.USD","SG9999014013.SGD","IE0004091025.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637312872","title":"BioAge Labs to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2637312872","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637312872?lang=en_us&edition=fundamental","pubTime":"2026-05-22 21:00","pubTimestamp":1779454800,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., May  22, 2026  (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) (\"BioAge\", \"the Company\"), a clinical-stage biotechnology company developing therapeutic product candidates for ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300131/0/en/BioAge-Labs-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786774","title":"BTIG Initiates BioAge Labs at Buy With $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786774","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786774?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:13","pubTimestamp":1778670802,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) has an average rating of overweight and mean price target of $51.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://bioagelabs.com","stockEarnings":[{"period":"1week","weight":0.1347},{"period":"1month","weight":0.0139},{"period":"3month","weight":0.48},{"period":"6month","weight":0.3086},{"period":"1year","weight":4.6222},{"period":"ytd","weight":0.8783}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.008123},{"month":2,"riseRate":0.4,"avgChangeRate":-0.16094},{"month":3,"riseRate":0.2,"avgChangeRate":-0.091972},{"month":4,"riseRate":0.4,"avgChangeRate":-0.044244},{"month":5,"riseRate":0,"avgChangeRate":-0.19738},{"month":6,"riseRate":0.25,"avgChangeRate":0.003055},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005696},{"month":8,"riseRate":0.4,"avgChangeRate":-0.229124},{"month":9,"riseRate":0.6,"avgChangeRate":0.004924},{"month":10,"riseRate":0.8,"avgChangeRate":0.181962},{"month":11,"riseRate":0.6,"avgChangeRate":0.056827},{"month":12,"riseRate":0.2,"avgChangeRate":-0.087267}],"exchange":"NASDAQ","name":"BioAge Labs Inc.","nameEN":"BioAge Labs Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioAge Labs Inc.,BIOA,BioAge Labs Inc.股票,BioAge Labs Inc.股票老虎,BioAge Labs Inc.股票老虎国际,BioAge Labs Inc.行情,BioAge Labs Inc.股票行情,BioAge Labs Inc.股价,BioAge Labs Inc.股市,BioAge Labs Inc.股票价格,BioAge Labs Inc.股票交易,BioAge Labs Inc.股票购买,BioAge Labs Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}